- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03798223
Optimal Treatment Protocol for Selective Laser Trabeculoplasty (OSLT)
Study Overview
Status
Intervention / Treatment
Detailed Description
A randomized controlled trial in which individuals scheduled for SLT are randomized to one of four treatment protocols, which represent the most common variants of the treatment in clinical use.
Treatment is performed either at 360 degrees or 180 degrees and with a laser energy level either 0,1 millijoules (mJ) below the microbubble formation limit ("low" energy) or at a level that gives microbubbles at 50-75% of laser effects ("high" energy). This gives four treatment arms: 180/low, 180/high, 360/low and 360/high. Group allocation is masked for the patient and is coded in the records.
The results for short and long term treatment effects are compared between the groups, as well as the complication rate and postoperative discomfort.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Vastra Gotaland
-
Boras, Vastra Gotaland, Sweden, 50182
- Ogonkliniken, Sodra Alvsborgs Sjukhus
-
Molndal, Vastra Gotaland, Sweden, 43130
- Ogonkliniken, Sahlgrenska Universitetssjukhuset
-
Skovde, Vastra Gotaland, Sweden, 54142
- Ogonkliniken, Skaraborgs Sjukhus
-
Uddevalla, Vastra Gotaland, Sweden, 45153
- Ogonkliniken NU-sjukvarden
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis primary open-angle glaucoma, pseudo-exfoliative glaucoma or ocular hypertension.
- intra-ocular pressure (IOP) at least 18 mmHg treatment day.
- treatment is performed by an experienced laser surgeon.
- SLT treatment and follow-up are expected to be possible to perform in an adequate way, considering anatomical factors, age and the general health of the patient.
Exclusion Criteria:
- change of IOP-lowering medication during the last three months.
- planned change of intra-ocular-pressure-lowering medication.
- previous glaucoma surgery (other than SLT and ALT)
- previous intra-ocular surgery during the last three months.
- previous intra-ocular inflammatory disease during the last year.
- planned intra-ocular surgery.
- hyper-pigmented anterior chamber angle.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 180/low
SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects.
The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
|
A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT.
Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered.
Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
|
Experimental: 180/high
SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects.
The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
|
A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT.
Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered.
Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
|
Experimental: 360/low
SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects.
The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
|
A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT.
Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered.
Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
|
Experimental: 360/high
SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects.
The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
|
A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT.
Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered.
Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in intraocular pressure (IOP)
Time Frame: Before SLT and thereafter regularly for 3 years
|
The IOP is measured with a Goldmann Applanation Tonometer (GAT) three times before SLT and then at regular intervals after the procedure. The reduction is registered and analyzed in absolute (mmHg) and relative (percent of the IOP before SLT) measures. Measurement of IOP is planned 1, 3, 6 and 12 months post SLT, and thereafter every six months for 3 years after SLT. The study is conducted in a regular clinical setting and the above mentioned times might be delayed. If target pressure is not achieved, measurements will be planned at shorter intervals, according to a specified algorithm, due to safety reasons. |
Before SLT and thereafter regularly for 3 years
|
Achievement of 20% reduction in IOP
Time Frame: For 3 years
|
See Outcome 1. Analysis of differences between the study arms will also be conducted measuring the proportion of eyes achieving 20% reduction in IOP or more at different time points in each group.
|
For 3 years
|
Survival (no additional intervention)
Time Frame: For 3 years
|
Kaplan-Meier survival analysis will be conducted, measuring the proportion of eyes that stay in the study groups but do not receive any further IOP-lowering intervention (medical, surgical or laser).
|
For 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival (SLT allowed)
Time Frame: For 3 years
|
See Outcome 3. Kaplan-Meier survival analysis is performed the same way, but additional SLT-treatment will not be judged as failure.
|
For 3 years
|
Pain perioperatively: on a scale
Time Frame: Immediately after treatment
|
The patient will grade perioperative pain on an arbitrary scale between 0 (no pain) and 4 (maximum pain) on a written protocol.
|
Immediately after treatment
|
Pain postoperatively: on a scale
Time Frame: During the first month
|
The patient will grade post-operative pain on an arbitrary scale between 0 (no pain) and 4 (maximum pain) on a written protocol, also stating the duration of pain.
|
During the first month
|
Light sensitivity postoperatively
Time Frame: During the first month
|
The patient will grade post-operative sensitivity to light on an arbitrary scale between 0 (no difference) and 4 (very intense sensitivity to light) on a written protocol, also stating the duration of light sensitivity.
|
During the first month
|
Impairment of vision postoperatively
Time Frame: During the first month
|
The patient will grade post-operative impairment of vision on an arbitrary scale between 0 (no difference) and 4 (cannot see ones own hand) on a written protocol, also stating the duration of vision impairment.
|
During the first month
|
Redness postoperatively
Time Frame: During the first month
|
The patient will grade post-operative redness of the eye on an arbitrary scale between 0 (no difference) and 4 (very intense redness) on a written protocol, also stating the duration of redness.
|
During the first month
|
Flare (inflammation measurement of the anterior chamber)
Time Frame: Pre-operatively and then one day, one week and one month post-operatively.
|
15 participants from each treatment arm (60 in total, randomized in a separate block after informed consent) will undergo measurement with a Laser Flare Meter.
|
Pre-operatively and then one day, one week and one month post-operatively.
|
Adverse events
Time Frame: 3 years (although adverse events, if any, are anticipated to emerge in the first post-operative days or weeks).
|
The type and frequency of adverse events will be recorded and analyzed in each of the study arms.
|
3 years (although adverse events, if any, are anticipated to emerge in the first post-operative days or weeks).
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Optimal SLT
- 254861 (Other Identifier: FoU i VGR ID nr)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on SLT
-
Meir Medical CenterCompletedPrimary Open Angle GlaucomaIsrael
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
BelkinVisionWithdrawnOcular Hypertension | Glaucoma, Open-Angle
-
University of KentuckyTerminated
-
University of ArkansasRecruiting
-
Carl Zeiss Meditec AGActive, not recruitingPrimary Open-angle GlaucomaGermany
-
Western University, CanadaCompletedOcular Hypertension | Intraocular Pressure | Primary Open Angle Glaucoma of Both EyesCanada
-
Technische Universität DresdenCompleted
-
Louisiana State University and A&M CollegeNot yet recruitingStroke | AphasiaUnited States
-
University of California, San DiegoWithdrawn